Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study
Berek, J. S., Markman, M., Blessing, J. A., Kucera, P. R., Nelson, B. E., Anderson, B., & Hanjani, P. (1999). Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 74(1), 48–52.

Intraperitoneal interferon-alpha in residual ovarian carcinoma: A Phase II Gynecologic Oncology Group study
Berek, J. S., Markman, M., Stonebraker, B., Lentz, S. S., Adelson, M. D., DeGeest, K., & Moore, D. (1999). Intraperitoneal interferon-alpha in residual ovarian carcinoma: A Phase II Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 75(1), 10–14.

Recurrent mature cystic teratoma presenting as a perihepatic mass
Chen, L. M., Nelson, S. D., & Berek, J. S. (1999). Recurrent mature cystic teratoma presenting as a perihepatic mass. OBSTETRICS AND GYNECOLOGY, 94(5), 856–856.

IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile
Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., & Parker, S. E. (1999). IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. JOURNAL OF IMMUNOLOGY, 163(12), 6378–6385.

Endometrial cancer: Recent developments in evaluation and treatment
Chen, L. M., McGonigle, K. F., & Berek, J. S. (1999). Endometrial cancer: Recent developments in evaluation and treatment. ONCOLOGY-NEW YORK, 13(12), 1665-?

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
Peters, W. A., Liu, P. Y., Barrett, R. J., Stock, R. J., Monk, B. J., Berek, J. S., … ALBERTS, D. S. (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. JOURNAL OF CLINICAL ONCOLOGY, 18(8), 1606–1613.

Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125
Berek, J. S. (2000). Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125. GYNECOLOGIC ONCOLOGY, 77(2), 225–226.

Ovarian cancer: Epidemiology, biology, and prognostic factors
Holschneider, C. H., & Berek, J. S. (2000). Ovarian cancer: Epidemiology, biology, and prognostic factors. SEMINARS IN SURGICAL ONCOLOGY, 19(1), 3–10.

Interferon plus chemotherapy for primary treatment of ovarian cancer
Berek, J. S. (2000). Interferon plus chemotherapy for primary treatment of ovarian cancer. LANCET, 356(9223), 6–7.

A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature
Ghosh, K., Dorigo, O., Bristow, R., & Berek, J. (2000). A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 191(2), 212–215.

[Epithelial ovarian cancer (advanced stage): consensus conference (1998)].
Berek, J. S., Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., Eisenhauer, E. A., … Willemse, P. H. (2000). [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Gynecologie, Obstetrique & Fertilite, 28(7-8), 576–583.

Fraud. What is the evidence?
Berek, J., Gutierrez, N., Stone, J., & Testa, L. (2000). Fraud. What is the evidence? Care Management Journals : Journal of Case Management ; The Journal of Long Term Home Health Care, 2(1), 44–53.

Advances in the management of epithelial ovarian cancer
Memarzadeh, S., & Berek, J. S. (2001). Advances in the management of epithelial ovarian cancer. JOURNAL OF REPRODUCTIVE MEDICINE, 46(7), 621–629.

Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis.
Fowler, J. M. M., Nieberg, R. K. K., Schooler, T. A. A., & Berek, J. S. S. (1994). Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 4(1), 43–51.

Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK.
Sharp, F., Blackett, A. D. D., Leake, R. E. E., & Berek, J. S. S. (1995). Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 5(6), 449–458.

FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival
Memarzadeh, S., Holschneider, C. H., Bristow, R. E., JONES, N. L., Fu, Y. S., Karlan, B. Y., … Farias-Eisner, R. (2002). FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 12(5), 454–458.

Specific keynote: Immunological therapy for ovarian cancer
Berek, J. S., Dorigo, O., Schultes, B., & Nicodemus, C. (2003). Specific keynote: Immunological therapy for ovarian cancer. GYNECOLOGIC ONCOLOGY, 88(1), S105–S109.

Simplification of the new Bethesda 2001 classification System
Berek, J. S. (2003). Simplification of the new Bethesda 2001 classification System. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 188(3), S2–S5.

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer
Memarzadeh, S., Lee, S. B., Berek, J. S., & Farias-Eisner, R. (2003). CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 13(2), 120–124.

The use of continuous infusion topotecan in persistent and recurrent ovarian cancer
Elkas, J. C., Holschneider, C. H., Katz, B., Li, A. J., Louie, R., McGonigle, K. F., & Berek, J. S. (2003). The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 13(2), 138–141.

Progress in the management of gynecologic cancer: consensus summary statement.
Cannistra, S. A., Bast, R. C., Berek, J. S., Bookman, M. A., Crum, C. P., DePriest, P. D., … King, L. (2003). Progress in the management of gynecologic cancer: consensus summary statement. Journal of Clinical Oncology , 21(10), 129s–132s.

Biologic and immunologic therapies for ovarian cancer.
Berek, J. S., Schultes, B. C., & Nicodemus, C. F. (2003). Biologic and immunologic therapies for ovarian cancer. Journal of Clinical Oncology , 21(10), 168s–174s.

Gene therapy for ovarian cancer: Development of novel treatment strategies
Dorigo, O., & Berek, J. S. (1997). Gene therapy for ovarian cancer: Development of novel treatment strategies. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 7(1), 1–13.

Surgical resection of solitary brain metastasis from cervical cancer
Tajran, D., & Berek, J. S. (2003). Surgical resection of solitary brain metastasis from cervical cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 13(3), 368–370.

Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
Fracasso, P. M., Blessing, J. A., Wolf, J., Rocereto, T. F., Berek, J. S., & Waggoner, S. (2003). Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 90(1), 177–180.

Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies
Gold, M. A., Walker, J. L., Berek, J. S., Hallum, A. V., Garcia, D. J., & ALBERTS, D. S. (2003). Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. GYNECOLOGIC ONCOLOGY, 90(2), 325–330.

Current research and treatment for epithelial ovarian cancer - A Position Paper from the Helene Harris Memorial Trust
Balkwill, F., Bast, R. C., Berek, J., Chenevix-Trench, G., Gore, M., Hamilton, T., … Smyth, J. (2003). Current research and treatment for epithelial ovarian cancer - A Position Paper from the Helene Harris Memorial Trust. EUROPEAN JOURNAL OF CANCER, 39(13), 1818–1827.

Lymphovascular and perineural invasion in the parametria: A prognostic factor for early-stage cervical cancer
Memarzadeh, S., Natarajan, S., Dandade, D. P., Ostrzega, N., Saber, P. A., Busuttil, A., … Berek, J. S. (2003). Lymphovascular and perineural invasion in the parametria: A prognostic factor for early-stage cervical cancer. OBSTETRICS AND GYNECOLOGY, 102(3), 612–619.

EARLY-STAGE SQUAMOUS-CELL AND ADENOCARCINOMA OF THE CERVIX
McGonigle, K. F., & Berek, J. S. (1992). EARLY-STAGE SQUAMOUS-CELL AND ADENOCARCINOMA OF THE CERVIX. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 4(1), 109–119.

PRESENCE OF INTERLEUKIN 10 (IL-10) IN THE ASCITES OF PATIENTS WITH OVARIAN AND OTHER INTRAABDOMINAL CANCERS
Gotlieb, W. H., Abrams, J. S., Watson, J. M., VELU, T. J., Berek, J. S., & MARTINEZMAZA, O. (1992). PRESENCE OF INTERLEUKIN 10 (IL-10) IN THE ASCITES OF PATIENTS WITH OVARIAN AND OTHER INTRAABDOMINAL CANCERS. CYTOKINE, 4(5), 385–390.

Cervical cancer: An opportunity to prevent and cure
Berek, J. S. (2003). Cervical cancer: An opportunity to prevent and cure. CANCER JOURNAL, 9(5), 325–326.

BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER
Bookman, M. A., & Berek, J. S. (1992). BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 6(4), 941–965.

Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy
Nouriani, M., Bahador, A., Berek, J. S., Cheng, J. P., Chi, D. S., Cliby, W. A., … Dubeau, L. (2004). Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. CLINICAL CANCER RESEARCH, 10(8), 2681–2686.

Using fresh tissue dissection to teach human anatomy in the clinical years
Robinson, A. G., Metten, S., Guiton, G., & Berek, J. (2004). Using fresh tissue dissection to teach human anatomy in the clinical years. ACADEMIC MEDICINE, 79(7), 711–716.

INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON
Berek, J. S. (1992). INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON. EUROPEAN JOURNAL OF CANCER, 28A(4-5), 719–721.

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab
Berek, J. S. (2004). Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. EXPERT OPINION ON BIOLOGICAL THERAPY, 4(7), 1159–1165.

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer
Berek, J. S., Taylor, P. T., Gordon, A., Cunningham, M. J., Finkler, N., Orr, J., … Nicodemus, C. F. (2004). Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(17), 3507–3516.

IMPROVING ADHERENCE TO SCREENING FOLLOW-UP AMONG WOMEN WITH ABNORMAL PAP SMEARS - RESULTS FROM A LARGE CLINIC-BASED TRIAL OF 3 INTERVENTION STRATEGIES
Marcus, A. C., Crane, L. A., Kaplan, C. P., READING, A. E., Savage, E., Gunning, J., … Berek, J. S. (1992). IMPROVING ADHERENCE TO SCREENING FOLLOW-UP AMONG WOMEN WITH ABNORMAL PAP SMEARS - RESULTS FROM A LARGE CLINIC-BASED TRIAL OF 3 INTERVENTION STRATEGIES. MEDICAL CARE, 30(3), 216–230.

STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1, INTERLEUKIN-6, AND TUMOR-NECROSIS-FACTOR-ALPHA
Wu, S., Rodabaugh, K., MARTINEZMAZA, O., Watson, J. M., Silberstein, D. S., BOYER, C. M., … Bast, R. C. (1992). STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1, INTERLEUKIN-6, AND TUMOR-NECROSIS-FACTOR-ALPHA. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 166(3), 997–1007.

Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study
Muggia, F. M., Blessing, J. A., Waggoner, S., Berek, J. S., Monk, B. J., Sorosky, J., & Pearl, M. L. (2005). Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. GYNECOLOGIC ONCOLOGY, 96(1), 108–111.

Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial
Monk, B. J., Wang, J. M., Im, S., Stock, R. J., Peters, W. A., Liu, P. Y., … ALBERTS, D. S. (2005). Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. GYNECOLOGIC ONCOLOGY, 96(3), 721–728.

Monoclonal antibody therapy of ovarian cancer
Nicodemus, C. F., & Berek, J. S. (2005). Monoclonal antibody therapy of ovarian cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 5(1), 87–96.

Lower urinary tract reconstruction with ileum in. the treatment of gynecologic malignancies
Elkas, J. C., Berek, J. S., Leuchter, R., Lagasse, L. D., & Karlan, B. Y. (2005). Lower urinary tract reconstruction with ileum in. the treatment of gynecologic malignancies. GYNECOLOGIC ONCOLOGY, 97(2), 685–692.

CHARACTERISTICS OF PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER UNRESPONSIVE TO CISPLATIN-BASED IP CHEMOTHERAPY - LESSONS LEARNED FROM A GYNECOLOGIC ONCOLOGY GROUP PHASE-II TRIAL OF IP CISPLATIN AND RECOMBINANT ALPHA-INTERFERON
Markman, M., Berek, J. S., Blessing, J. A., McGuire, W. P., Bell, J., & Homesley, H. D. (1992). CHARACTERISTICS OF PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER UNRESPONSIVE TO CISPLATIN-BASED IP CHEMOTHERAPY - LESSONS LEARNED FROM A GYNECOLOGIC ONCOLOGY GROUP PHASE-II TRIAL OF IP CISPLATIN AND RECOMBINANT ALPHA-INTERFERON. GYNECOLOGIC ONCOLOGY, 45(1), 3–8.

Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA
Berek, J. S., Howe, C., Lagasse, L. D., & Hacker, N. F. (2005). Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA. GYNECOLOGIC ONCOLOGY, 99(1), 153–159.

Design, conduct and evaluation of a communication course for oncology fellows
Lenzi, R., Baile, W. F., Berek, J., Back, A., Buckman, R., Cohen, L., & Parker, P. A. (2005). Design, conduct and evaluation of a communication course for oncology fellows. JOURNAL OF CANCER EDUCATION, 20(3), 143–149.

An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer
Bryan, D. N., Radbod, R., & Berek, J. S. (2006). An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 16(1), 125–134.

10th Biennial Helene Harris Memorial Trust Meeting
Balkwill, F. R., Ashworth, A., Bast, R. C., Berek, J. S., Boyd, J., Disis, M. L., … Urban, N. D. (2006). 10th Biennial Helene Harris Memorial Trust Meeting. CANCER RESEARCH, 66(6), 2904–2906.

Progress in ovarian cancer research: Proceedings of the 5th biennial ovarian cancer research symposium
Disis, M. L., Rivkin, S. E., Baron, A., Markman, M., Connolly, D., Ueland, F., … Berek, J. S. (2006). Progress in ovarian cancer research: Proceedings of the 5th biennial ovarian cancer research symposium. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 16(2), 463–69.

Surgery for ovarian cancer: how to improve survival
Bristow, R. E., & Berek, J. S. (2006). Surgery for ovarian cancer: how to improve survival. LANCET, 367(9522), 1558–1560.

The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma
Parthasarathy, A., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., Berek, J. S., … Chan, J. K. (2006). The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. GYNECOLOGIC ONCOLOGY, 103(3), 1095–99.

Intraperitoneal chemotherapy for ovarian cancer
Hamilton, C. A., & Berek, J. S. (2006). Intraperitoneal chemotherapy for ovarian cancer. CURRENT OPINION IN ONCOLOGY, 18(5), 507–515.

RISK-FACTORS FOR THE DEVELOPMENT OF LYMPH-NODE METASTASIS IN VULVAR SQUAMOUS-CELL CARCINOMA
Binder, S. W., Huang, I., Fu, Y. S., Hacker, N. F., & Berek, J. S. (1990). RISK-FACTORS FOR THE DEVELOPMENT OF LYMPH-NODE METASTASIS IN VULVAR SQUAMOUS-CELL CARCINOMA. GYNECOLOGIC ONCOLOGY, 37(1), 9–16.

Patterns and progress in ovarian cancer over 14 years
Chan, J. K., Cheung, M. K., Husain, A., Teng, N. N., West, D., Whittemore, A. S., … Osann, K. (2006). Patterns and progress in ovarian cancer over 14 years. OBSTETRICS AND GYNECOLOGY, 108(3), 521–28.

Response to commentaries on retention of the ovaries and long-term survival after hysterectomy
Parker, W. H., Broder, M. S., Liu, Z., Shoupe, D., Farquhar, C., & Berek, J. S. (2006). Response to commentaries on retention of the ovaries and long-term survival after hysterectomy. CLIMACTERIC, 9(5), 396–398.

Prognostic factors responsible for survival in sex cord stromal tumors of the ovary- An analysis of 376 women
Zhang, M., Cheung, M. K., Shin, J. Y., Kapp, D. S., Husain, A., Teng, N. N., … Chan, J. K. (2007). Prognostic factors responsible for survival in sex cord stromal tumors of the ovary- An analysis of 376 women. GYNECOLOGIC ONCOLOGY, 104(2), 396–400.

Ovarian cancer in younger vs older women: a population-based analysis
Chan, J. K., Urban, R., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., … Leiserowitz, G. S. (2006). Ovarian cancer in younger vs older women: a population-based analysis. BRITISH JOURNAL OF CANCER, 95(10), 1314–1320.

Association of lymphadenectomy and survival in stage I ovarian cancer patients
Chan, J. K., Munro, E. G., Cheung, M. K., Husain, A., Teng, N. N., Berek, J. S., & Osann, K. (2007). Association of lymphadenectomy and survival in stage I ovarian cancer patients. OBSTETRICS AND GYNECOLOGY, 109(1), 12–19.

2ND-LOOK VERSUS 2ND NATURE
Berek, J. S. (1992). 2ND-LOOK VERSUS 2ND NATURE. GYNECOLOGIC ONCOLOGY, 44(1), 1–2.

CA125: Megadaltons of novel opportunities
Dorigo, O., & Berek, J. S. (2007). CA125: Megadaltons of novel opportunities. GYNECOLOGIC ONCOLOGY, 104(3), 505–507.

Prognostic factors for uterine cancer in reproductive-aged women
Lee, N. K., Cheung, M. K., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., … Chan, J. K. (2007). Prognostic factors for uterine cancer in reproductive-aged women. OBSTETRICS AND GYNECOLOGY, 109(3), 655–62.

Elective oophorectomy for benign gynecological disorders
Shoupe, D., Parker, W. H., Broder, M. S., Liu, Z., Farquhar, C., & Berek, J. S. (2007). Elective oophorectomy for benign gynecological disorders. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 14(3), 580–85.

Lymphadenectomy in endometrioid uterine cancer staging - How many lymph nodes are enough? A study of 11,443 patients
Chan, J. K., Urban, R., Cheung, M. K., Shin, J. Y., Husain, A., Teng, N. N., … Osann, K. (2007). Lymphadenectomy in endometrioid uterine cancer staging - How many lymph nodes are enough? A study of 11,443 patients. CANCER, 109(12), 2454–60.

Ovarian conservation at the time of hysterectomy for benign disease
Parker, W. H., Broder, M. S., Liu, Z., Shoupe, D., Farquhar, C., & Berek, J. S. (2007). Ovarian conservation at the time of hysterectomy for benign disease. CLINICAL OBSTETRICS AND GYNECOLOGY, 50(2), 354–61.

The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients
Chan, J. K., Urban, R., Hu, J. M., Shin, J. Y., Husain, A., Teng, N. N., … Kapp, D. S. (2007). The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients. BRITISH JOURNAL OF CANCER, 96(12), 1817–1822.

Influence of the gynecologic oncologist on the survival of ovarian cancer patients
Chan, J. K., Kapp, D. S., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., … O'Malley, C. (2007). Influence of the gynecologic oncologist on the survival of ovarian cancer patients. OBSTETRICS AND GYNECOLOGY, 109(6), 1342–50.

Impact of the human papilloma vaccine on cervical cancer
Chan, J. K., & Berek, J. S. (2007). Impact of the human papilloma vaccine on cervical cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(20), 2975–82.

Elective oophorectomy in the gynecological patient: when is it desirable?
Parker, W. H., Shoupe, D., Broder, M. S., Liu, Z., Farquhar, C., & Berek, J. S. (2007). Elective oophorectomy in the gynecological patient: when is it desirable? CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 19(4), 350–54.

Vulvar melanoma - A multivariable analysis of 644 patients
Sugiyama, V. E., Chan, J. K., Shin, J. Y., Berek, J. S., Osann, K., & Kapp, D. S. (2007). Vulvar melanoma - A multivariable analysis of 644 patients. OBSTETRICS AND GYNECOLOGY, 110(2), 296–301.

Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007
Ashworth, A., Balkwill, F., Bast, R. C., Berek, J. S., Kaye, A., Boyd, J. A., … Workman, P. (2008). Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. GYNECOLOGIC ONCOLOGY, 108(3), 652–657.

Interleukin 6 and cancer treatment.
Martínez-Maza, O., & Berek, J. S. (1991). Interleukin 6 and cancer treatment. In Vivo , 5(6), 583–588.

Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer
Chan, J. K., Kapp, D. S., Cheung, M. K., Shin, J. Y., Stieglitz, D., Husain, A., … Guo, H. (2008). Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 198(2).

Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths
Ueda, S. M., Kapp, D. S., Cheung, M. K., Shin, J. Y., Osann, K., Husain, A., … Chan, J. K. (2008). Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 198(2).

HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review
Karam, A., Berek, J. S., Stenson, A., Rao, J., & Dorigo, O. (2008). HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. GYNECOLOGIC ONCOLOGY, 111(3), 568–71.

CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer
Berek, J. S., Taylor, P. T., & Nicodemus, C. F. (2008). CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. JOURNAL OF IMMUNOTHERAPY, 31(2), 207–214.

Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
Berek, J., Taylor, P., McGuire, W., Smith, L. M., Schultes, B., & Nicodemus, C. F. (2009). Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27(3), 418–25.

Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses' Health Study
Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., … Manson, J. A. E. (2009). Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses' Health Study. OBSTETRICS AND GYNECOLOGY, 113(5), 1027–37.

Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer The Gynecologic Oncology Group Experience
Markman, M., Brady, M., Hutson, A., & Berek, J. S. (2009). Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer The Gynecologic Oncology Group Experience. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 19(2), 223–229.

CONCURRENT CISPLATIN AND 5-FLUOROURACIL CHEMOTHERAPY AND RADIATION-THERAPY FOR ADVANCED-STAGE SQUAMOUS CARCINOMA OF THE VULVA
Berek, J. S., HEAPS, J. M., Fu, Y. S., Juillard, G. J. F., & Hacker, N. F. (1991). CONCURRENT CISPLATIN AND 5-FLUOROURACIL CHEMOTHERAPY AND RADIATION-THERAPY FOR ADVANCED-STAGE SQUAMOUS CARCINOMA OF THE VULVA. GYNECOLOGIC ONCOLOGY, 42(3), 197–201.

RESISTANCE OF HUMAN OVARIAN-CANCER CELLS TO TUMOR-NECROSIS-FACTOR AND LYMPHOKINE-ACTIVATED KILLER-CELLS - CORRELATION WITH EXPRESSION OF HER2 NEU ONCOGENES
Lichtenstein, A., Berenson, J., Gera, J. F., Waldburger, K., MARTINEZMAZA, O., & Berek, J. S. (1990). RESISTANCE OF HUMAN OVARIAN-CANCER CELLS TO TUMOR-NECROSIS-FACTOR AND LYMPHOKINE-ACTIVATED KILLER-CELLS - CORRELATION WITH EXPRESSION OF HER2 NEU ONCOGENES. CANCER RESEARCH, 50(22), 7364–7370.

FINE-NEEDLE ASPIRATION CYTOLOGY ACCURACY WITH PALPABLE GYNECOLOGIC NEOPLASMS
Layfield, L. J., HEAPS, J. M., & Berek, J. S. (1991). FINE-NEEDLE ASPIRATION CYTOLOGY ACCURACY WITH PALPABLE GYNECOLOGIC NEOPLASMS. GYNECOLOGIC ONCOLOGY, 40(1), 70–73.

Lymph Node-Positive Stage IIIC Ovarian Cancer A Separate Entity?
Berek, J. S. (2009). Lymph Node-Positive Stage IIIC Ovarian Cancer A Separate Entity? Presented at the International Symposium on Advanced Ovarian Cancer - Optimal Therapy, VALENCIA,SPAIN: LIPPINCOTT WILLIAMS & WILKINS.

Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy
Nicodemus, C. F., Wang, L., Lucas, J., Varghese, B., & Berek, J. S. (2010). Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. LA JOLLA,CA,CA,CA,CA: MOSBY-ELSEVIER.

A PHASE I-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ALPHA-INTERFERON IN PATIENTS WITH PERSISTENT EPITHELIAL OVARIAN-CANCER
Berek, J. S., WELANDER, C., Schink, J. C., Grossberg, H., Montz, F. J., & ZIGELBOIM, J. (1991). A PHASE I-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ALPHA-INTERFERON IN PATIENTS WITH PERSISTENT EPITHELIAL OVARIAN-CANCER. GYNECOLOGIC ONCOLOGY, 40(3), 237–243.

SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER
Berek, J. S., Chung, C., Kaldi, K., Watson, J. M., Knox, R. M., & MARTINEZMAZA, O. (1991). SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 164(4), 1038–1043.

ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING OF VULVAR CARCINOMA RELATIVE TO PROGNOSTIC FACTORS FOR SURVIVAL (A GYNECOLOGIC ONCOLOGY GROUP-STUDY)
Homesley, H. D., Bundy, B. N., Sedlis, A., YORDAN, E., Berek, J. S., Jahshan, A., & MORTEL, R. (1991). ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING OF VULVAR CARCINOMA RELATIVE TO PROGNOSTIC FACTORS FOR SURVIVAL (A GYNECOLOGIC ONCOLOGY GROUP-STUDY). AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 164(4), 997–1004.

ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMINAL-PAIN IN POSTMENOPAUSAL WOMEN
Shih, S., Vetto, J. T., Berek, J. S., HEAPS, J. M., & Hiatt, J. R. (1991). ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMINAL-PAIN IN POSTMENOPAUSAL WOMEN. AMERICAN SURGEON, 57(5), 327–329.

Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy Recommendations Based on Risk of Ovarian Cancer
Berek, J. S., Chalas, E., Edelson, M., Moore, D. H., Burke, W. M., Cliby, W. A., & Berchuck, A. (2010). Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy Recommendations Based on Risk of Ovarian Cancer. OBSTETRICS AND GYNECOLOGY, 116(3), 733–43.

Strategies and Goals: The Future of the International Gynecologic Cancer Society IGCS Presidential Address
Berek, J. S. (2010). Strategies and Goals: The Future of the International Gynecologic Cancer Society IGCS Presidential Address. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 20(9), 1434–1439.

MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN BY OPERATIVE LAPAROSCOPY - A PILOT-STUDY
Parker, W. H., & Berek, J. S. (1990). MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN BY OPERATIVE LAPAROSCOPY - A PILOT-STUDY. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 163(5), 1574–1577.

ADJUVANT THERAPY FOR EARLY-STAGE OVARIAN-CANCER
Berek, J. S. (1990). ADJUVANT THERAPY FOR EARLY-STAGE OVARIAN-CANCER. NEW ENGLAND JOURNAL OF MEDICINE, 322(15), 1076–1078.

MALIGNANT NEOPLASMS ARISING IN ENDOMETRIOSIS
HEAPS, J. M., Nieberg, R. K., & Berek, J. S. (1990). MALIGNANT NEOPLASMS ARISING IN ENDOMETRIOSIS. OBSTETRICS AND GYNECOLOGY, 75(6), 1023–1028.

Personalizing CA125 Levels for Ovarian Cancer Screening
Dorigo, O., & Berek, J. S. (2011). Personalizing CA125 Levels for Ovarian Cancer Screening. CANCER PREVENTION RESEARCH, 4(9), 1356–1359.

PATHOPHYSIOLOGY AND MANAGEMENT OF ENDOMETRIAL HYPERPLASIA AND CARCINOMA
Fu, Y. S., Gambone, J. C., Do, & Berek, J. S. (1990). PATHOPHYSIOLOGY AND MANAGEMENT OF ENDOMETRIAL HYPERPLASIA AND CARCINOMA. WESTERN JOURNAL OF MEDICINE, 153(1), 50–61.

CONSTITUTIVE PRODUCTION OF INTERLEUKIN-6 BY OVARIAN-CANCER CELL-LINES AND BY PRIMARY OVARIAN TUMOR CULTURES
Watson, J. M., Sensintaffar, J. L., Berek, J. S., & MARTINEZMAZA, O. (1990). CONSTITUTIVE PRODUCTION OF INTERLEUKIN-6 BY OVARIAN-CANCER CELL-LINES AND BY PRIMARY OVARIAN TUMOR CULTURES. CANCER RESEARCH, 50(21), 6959–6965.

INTRAPERITONEAL ADOPTIVE IMMUNOTHERAPY FOR PERITONEAL CANCER
Berek, J. S. (1990). INTRAPERITONEAL ADOPTIVE IMMUNOTHERAPY FOR PERITONEAL CANCER. JOURNAL OF CLINICAL ONCOLOGY, 8(10), 1610–1612.

OVARIAN METASTASES ARE RARE IN STAGE-I ADENOCARCINOMA OF THE CERVIX
Brown, J. V., Fu, Y. S., & Berek, J. S. (1990). OVARIAN METASTASES ARE RARE IN STAGE-I ADENOCARCINOMA OF THE CERVIX. OBSTETRICS AND GYNECOLOGY, 76(4), 623–623.

Current Management of Vulvar Cancer
Fuh, K. C., & Berek, J. S. (2012). Current Management of Vulvar Cancer. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 26(1), 45-?

SURGICAL-PATHOLOGICAL VARIABLES PREDICTIVE OF LOCAL RECURRENCE IN SQUAMOUS-CELL CARCINOMA OF THE VULVA
HEAPS, J. M., Fu, Y. S., Montz, F. J., Hacker, N. F., & Berek, J. S. (1990). SURGICAL-PATHOLOGICAL VARIABLES PREDICTIVE OF LOCAL RECURRENCE IN SQUAMOUS-CELL CARCINOMA OF THE VULVA. GYNECOLOGIC ONCOLOGY, 38(3), 309–314.

SYNERGY IS DOCUMENTED INVITRO WITH LOW-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR, CISPLATIN, AND DOXORUBICIN IN OVARIAN-CANCER CELLS
Bonavida, B., Tsuchitani, T., ZIGHELBOIM, J., & Berek, J. S. (1990). SYNERGY IS DOCUMENTED INVITRO WITH LOW-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR, CISPLATIN, AND DOXORUBICIN IN OVARIAN-CANCER CELLS. GYNECOLOGIC ONCOLOGY, 38(3), 333–339.

FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage
Chung, Y. M., Park, S.-H., Tsai, W.-B., Wang, S.-Y., Ikeda, M.-A., Berek, J. S., … Hu, M. C. T. (2012). FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. NATURE COMMUNICATIONS, 3.

SURGICAL STAGING OF CERVICAL-CANCER
HEAPS, J. M., & Berek, J. S. (1990). SURGICAL STAGING OF CERVICAL-CANCER. CLINICAL OBSTETRICS AND GYNECOLOGY, 33(4), 852–863.

Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C., & Friedlander, M. (2012). Cancer of the ovary, fallopian tube, and peritoneum. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 119, S118–S129.

PELVIC HEMANGIOPERICYTOMAS - A REPORT OF 5 CASES AND LITERATURE-REVIEW
Munoz, A. K., Berek, J. S., Fu, Y. S., & HEINTZ, P. A. M. (1990). PELVIC HEMANGIOPERICYTOMAS - A REPORT OF 5 CASES AND LITERATURE-REVIEW. GYNECOLOGIC ONCOLOGY, 36(3), 380–382.

CYCLOHEXIMIDE-INDUCED MODULATION OF TNF-MEDIATED CYTOTOXICITY IN SENSITIVE AND RESISTANT OVARIAN TUMOR-CELLS
Nio, Y., ZIGHELBOIM, J., Berek, J., & Bonavida, B. (1990). CYCLOHEXIMIDE-INDUCED MODULATION OF TNF-MEDIATED CYTOTOXICITY IN SENSITIVE AND RESISTANT OVARIAN TUMOR-CELLS. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 26(1), 1–8.

AUGMENTATION OF CYTOTOXICITY OF LYMPHOKINE ACTIVATED KILLER-CELLS ON OVARIAN TUMOR-CELLS BY VARIOUS BIOLOGICAL RESPONSE MODIFIERS
Nio, Y., ZIGHELBOIM, J., Berek, J. S., & Bonavida, B. (1990). AUGMENTATION OF CYTOTOXICITY OF LYMPHOKINE ACTIVATED KILLER-CELLS ON OVARIAN TUMOR-CELLS BY VARIOUS BIOLOGICAL RESPONSE MODIFIERS. ANTICANCER RESEARCH, 10(2A), 441–446.

Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study
Sabbatini, P., Harter, P., Scambia, G., Sehouli, J., Meier, W., Wimberger, P., … Pfisterer, J. (2013). Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study. JOURNAL OF CLINICAL ONCOLOGY. CHICAGO,IL,IL,IL: AMER SOC CLINICAL ONCOLOGY.

CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN-CANCER - CARDIOVASCULAR EVALUATION WITH PULMONARY-ARTERY CATHETERS
EISNER, R. F., Montz, F. J., & Berek, J. S. (1990). CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN-CANCER - CARDIOVASCULAR EVALUATION WITH PULMONARY-ARTERY CATHETERS. GYNECOLOGIC ONCOLOGY, 37(3), 311–314.

Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study
Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., … Manson, J. A. E. (2013). Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study. OBSTETRICS AND GYNECOLOGY, 121(4), 709–16.

PHASE-II STUDY OF N-METHYLFORMAMIDE (N-MF) (NSC 3051) IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
McGuire, W. P., Blessing, J. A., Berek, J. S., & Munoz, A. (1990). PHASE-II STUDY OF N-METHYLFORMAMIDE (N-MF) (NSC 3051) IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. INVESTIGATIONAL NEW DRUGS, 8(2), 191–194.

CA 125 FOR THE MONITORING OF OVARIAN-CARCINOMA DURING PRIMARY THERAPY
Lavin, P. T., Knapp, R. C., MALKASIAN, G., Whitney, C. W., BEREK, J. C., & Bast, R. C. (1987). CA 125 FOR THE MONITORING OF OVARIAN-CARCINOMA DURING PRIMARY THERAPY. OBSTETRICS AND GYNECOLOGY, 69(2), 223–227.

PREOPERATIVE EVALUATION OF SERUM CA-125 LEVELS IN PREMENOPAUSAL AND POSTMENOPAUSAL PATIENTS WITH PELVIC MASSES - DISCRIMINATION OF BENIGN FROM MALIGNANT DISEASE
Malkasian, G. D., Knapp, R. C., Lavin, P. T., Zurawski, V. R., Podratz, K. C., Stanhope, C. R., … RITTS, R. E. (1988). PREOPERATIVE EVALUATION OF SERUM CA-125 LEVELS IN PREMENOPAUSAL AND POSTMENOPAUSAL PATIENTS WITH PELVIC MASSES - DISCRIMINATION OF BENIGN FROM MALIGNANT DISEASE. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 159(2), 341–346.

Screening, diagnosis, and monitoring of gynecologic malignancies.
Montz, F. J., & Berek, J. S. (1989). Screening, diagnosis, and monitoring of gynecologic malignancies. Current Opinion in Oncology, 1(1), 75–81.

HUMAN NEUTROPHIL-MEDIATED LYSIS OF OVARIAN-CANCER CELLS
Lichtenstein, A., Seelig, M., Berek, J., & ZIGHELBOIM, J. (1989). HUMAN NEUTROPHIL-MEDIATED LYSIS OF OVARIAN-CANCER CELLS. BLOOD, 74(2), 805–809.

RESECTION OF DIAPHRAGMATIC PERITONEUM AND MUSCLE - ROLE IN CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER
Montz, F. J., Schlaerth, J. B., & Berek, J. S. (1989). RESECTION OF DIAPHRAGMATIC PERITONEUM AND MUSCLE - ROLE IN CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER. GYNECOLOGIC ONCOLOGY, 35(3), 338–340.

VULVOVAGINAL MELANOMA - REPORT OF 7 CASES AND LITERATURE-REVIEW
Brand, E., Fu, Y. S., Lagasse, L. D., & Berek, J. S. (1989). VULVOVAGINAL MELANOMA - REPORT OF 7 CASES AND LITERATURE-REVIEW. GYNECOLOGIC ONCOLOGY, 33(1), 54–60.

SYNCHRONOUS PRIMARY NEOPLASMS OF THE FEMALE REPRODUCTIVE-TRACT
EISNER, R. F., Nieberg, R. K., & Berek, J. S. (1989). SYNCHRONOUS PRIMARY NEOPLASMS OF THE FEMALE REPRODUCTIVE-TRACT. GYNECOLOGIC ONCOLOGY, 33(3), 335–339.

CYTO-TOXIC AND CYTOSTATIC EFFECTS OF THE STREPTOCOCCAL PREPARATION OK-432 AND ITS SUBCELLULAR-FRACTIONS ON HUMAN OVARIAN TUMOR-CELLS
Nio, Y., ZIGHELBOIM, J., Berek, J., & Bonavida, B. (1989). CYTO-TOXIC AND CYTOSTATIC EFFECTS OF THE STREPTOCOCCAL PREPARATION OK-432 AND ITS SUBCELLULAR-FRACTIONS ON HUMAN OVARIAN TUMOR-CELLS. CANCER, 64(2), 434–441.

UTILIZATION OF A MURINE MODEL TO OPTIMIZE VOLUME AND DWELL TIME OF INTRAPERITONEAL CISPLATIN
Pretorius, R. G., Eisenkop, S., Berek, J. S., Hacker, N. F., Ashikaga, T., Knox, R. M., & Lagasse, L. D. (1989). UTILIZATION OF A MURINE MODEL TO OPTIMIZE VOLUME AND DWELL TIME OF INTRAPERITONEAL CISPLATIN. GYNECOLOGIC ONCOLOGY, 34(1), 66–69.

LYMPHOCYTE-ACTIVATION BY RECOMBINANT INTERLEUKIN-2 IN OVARIAN-CANCER PATIENTS
Boyer, P. J., Berek, J. S., & ZIGHELBOIM, J. (1989). LYMPHOCYTE-ACTIVATION BY RECOMBINANT INTERLEUKIN-2 IN OVARIAN-CANCER PATIENTS. OBSTETRICS AND GYNECOLOGY, 73(5), 793–797.

SYNERGISTIC EFFECT OF COMBINED INTRAPERITONEAL CISPLATIN AND CYTOSINE-ARABINOSIDE IN A MURINE OVARIAN-CANCER MODEL
Berek, J. S., Schink, J. C., & Knox, R. M. (1989). SYNERGISTIC EFFECT OF COMBINED INTRAPERITONEAL CISPLATIN AND CYTOSINE-ARABINOSIDE IN A MURINE OVARIAN-CANCER MODEL. OBSTETRICS AND GYNECOLOGY, 74(4), 663–666.

RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE PLUS CISPLATIN WITH OR WITHOUT DOXORUBICIN IN OVARIAN-CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
Omura, G. A., Bundy, B. N., Berek, J. S., Curry, S., Delgado, G., & MORTEL, R. (1989). RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE PLUS CISPLATIN WITH OR WITHOUT DOXORUBICIN IN OVARIAN-CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. JOURNAL OF CLINICAL ONCOLOGY, 7(4), 457–465.

INTRAPERITONEAL IMMUNOTHERAPY OF EPITHELIAL OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM
Berek, J. S., Knapp, R. C., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., … Bast, R. C. (1985). INTRAPERITONEAL IMMUNOTHERAPY OF EPITHELIAL OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 152(8), 1003–1010.

CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA - FEASIBILITY AND MORBIDITY
Heintz, A. P. M., Hacker, N. F., Berek, J. S., Rose, T. P., Munoz, A. K., & Lagasse, L. D. (1986). CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA - FEASIBILITY AND MORBIDITY. OBSTETRICS AND GYNECOLOGY, 67(6), 783–788.

HUMAN PAPILLOMAVIRUS DEOXYRIBONUCLEIC-ACID IN ADENOCARCINOMA AND ADENOSQUAMOUS CARCINOMA OF THE UTERINE CERVIX
Smotkin, D., Berek, J. S., Fu, Y. S., Hacker, N. F., Major, F. J., & WETTSTEIN, F. O. (1986). HUMAN PAPILLOMAVIRUS DEOXYRIBONUCLEIC-ACID IN ADENOCARCINOMA AND ADENOSQUAMOUS CARCINOMA OF THE UTERINE CERVIX. OBSTETRICS AND GYNECOLOGY, 68(2), 241–244.

IMMUNOLOGICAL CONTROL OF OVARIAN-CANCER
ZIGHELBOIM, J., Nio, Y., Berek, J. S., & Bonavida, B. (1988). IMMUNOLOGICAL CONTROL OF OVARIAN-CANCER. NATURAL IMMUNITY AND CELL GROWTH REGULATION, 7(4), 216–225.

INTRAPERITONEAL ADMINISTRATION OF HUMAN RECOMBINANT INTERFERON-ALPHA IN PATIENTS WITH OVARIAN-CANCER - EFFECTS ON LYMPHOCYTE PHENOTYPE AND CYTO-TOXICITY
Lichtenstein, A., Spina, C., Berek, J. S., Jung, T., & ZIGHELBOIM, J. (1988). INTRAPERITONEAL ADMINISTRATION OF HUMAN RECOMBINANT INTERFERON-ALPHA IN PATIENTS WITH OVARIAN-CANCER - EFFECTS ON LYMPHOCYTE PHENOTYPE AND CYTO-TOXICITY. CANCER RESEARCH, 48(20), 5853–5859.

PERITONEAL CYTOLOGY OF OVARIAN-CANCER PATIENTS RECEIVING INTRAPERITONEAL THERAPY - QUANTITATION OF MALIGNANT-CELLS AND RESPONSE
Sagae, S., Berek, J. S., Fu, Y. S., Chang, N., Dauplat, J., & Hacker, N. F. (1988). PERITONEAL CYTOLOGY OF OVARIAN-CANCER PATIENTS RECEIVING INTRAPERITONEAL THERAPY - QUANTITATION OF MALIGNANT-CELLS AND RESPONSE. OBSTETRICS AND GYNECOLOGY, 72(5), 782–788.

SENSITIVITY OF FRESH AND CULTURED OVARIAN TUMOR-CELLS TO TUMOR NECROSIS FACTOR, INTERFERON-ALPHA-2, AND OK-432
Nio, Y., ZIGHELBOIM, J., Berek, J. S., & Bonavida, B. (1988). SENSITIVITY OF FRESH AND CULTURED OVARIAN TUMOR-CELLS TO TUMOR NECROSIS FACTOR, INTERFERON-ALPHA-2, AND OK-432. CANCER IMMUNOLOGY IMMUNOTHERAPY, 27(3), 246–254.

CONTROVERSIES IN THE MANAGEMENT OF CERVICAL ADENOCARCINOMA
Brand, E., Berek, J. S., & Hacker, N. F. (1988). CONTROVERSIES IN THE MANAGEMENT OF CERVICAL ADENOCARCINOMA. OBSTETRICS AND GYNECOLOGY, 71(2), 261–269.

Minimal cervical cancer: definition and histology.
Fu, Y. S., & Berek, J. S. (1988). Minimal cervical cancer: definition and histology. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer, 106, 47–56.

Uterine corpus and cervical cancer.
Berek, J. S., Hacker, N. F., Hatch, K. D., & Young, R. C. (1988). Uterine corpus and cervical cancer. Current Problems in Cancer, 12(2), 61–131.

CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS
Berek, J. S., Knapp, R. C., Malkasian, G. D., Lavin, P. T., Whitney, C., Niloff, J. M., & Bast, R. C. (1986). CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS. OBSTETRICS AND GYNECOLOGY, 67(5), 685–689.

THE CA 125 ASSAY AS A PREDICTOR OF CLINICAL RECURRENCE IN EPITHELIAL OVARIAN-CANCER
Niloff, J. M., Knapp, R. C., Lavin, P. T., Malkasian, G. D., Berek, J. S., MORTEL, R., … Bast, R. C. (1986). THE CA 125 ASSAY AS A PREDICTOR OF CLINICAL RECURRENCE IN EPITHELIAL OVARIAN-CANCER. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 155(1), 56–60.

PROGNOSTIC-SIGNIFICANCE OF DNA PLOIDY AND MORPHOMETRIC ANALYSES OF ADENOCARCINOMA OF THE UTERINE CERVIX
Fu, Y. S., Hall, T. L., Berek, J. S., Hacker, N. F., & Reagan, J. W. (1987). PROGNOSTIC-SIGNIFICANCE OF DNA PLOIDY AND MORPHOMETRIC ANALYSES OF ADENOCARCINOMA OF THE UTERINE CERVIX. ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, 9(1), 17–24.

Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix.
Fu, Y. S., Berek, J. S., & Hilborne, L. H. (1987). Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix. Applied Pathology, 5(1), 47–56.

RHABDOMYOSARCOMA OF THE UTERINE CERVIX - SARCOMA BOTRYOIDES
Brand, E., Berek, J. S., Nieberg, R. K., & Hacker, N. F. (1987). RHABDOMYOSARCOMA OF THE UTERINE CERVIX - SARCOMA BOTRYOIDES. CANCER, 60(7), 1552–1560.

DISTANT METASTASES IN EPITHELIAL OVARIAN-CARCINOMA
Dauplat, J., Hacker, N. F., Nieberg, R. K., Berek, J. S., Rose, T. P., & Sagae, S. (1987). DISTANT METASTASES IN EPITHELIAL OVARIAN-CARCINOMA. CANCER, 60(7), 1561–1566.

INTRAPERITONEAL CISPLATINUM AS SALVAGE THERAPY FOR REFRACTORY EPITHELIAL OVARIAN-CANCER
Hacker, N. F., Berek, J. S., Pretorius, R. G., Zuckerman, J., Eisenkop, S., & Lagasse, L. D. (1987). INTRAPERITONEAL CISPLATINUM AS SALVAGE THERAPY FOR REFRACTORY EPITHELIAL OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 70(5), 759–764.

ANTITUMOR AND IMMUNOLOGICAL EFFECTS OF A PYRIDINE-EXTRACTED FRACTION OF PROPIONIBACTERIUM-ACNES
Lichtenstein, A., & Berek, J. (1986). ANTITUMOR AND IMMUNOLOGICAL EFFECTS OF A PYRIDINE-EXTRACTED FRACTION OF PROPIONIBACTERIUM-ACNES. CANCER IMMUNOLOGY IMMUNOTHERAPY, 22(1), 24–30.

Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Knox, R. M., … Lagasse, L. D. (1985). Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer. Cancer Treatment Reviews, 12, 23–32.

NATURAL-KILLER INHIBITORY SUBSTANCE PRODUCED BY THE PERITONEAL-CELLS OF PATIENTS WITH OVARIAN-CANCER
Lichtenstein, A. K., Berek, J., & ZIGHELBOIM, J. (1985). NATURAL-KILLER INHIBITORY SUBSTANCE PRODUCED BY THE PERITONEAL-CELLS OF PATIENTS WITH OVARIAN-CANCER. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 74(2), 349–355.

PHASE-II TRIAL OF CISPLATIN IN ADVANCED OR RECURRENT CANCER OF THE VAGINA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
Thigpen, J. T., Blessing, J. A., Homesley, H. D., Berek, J. S., & Creasman, W. T. (1986). PHASE-II TRIAL OF CISPLATIN IN ADVANCED OR RECURRENT CANCER OF THE VAGINA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. GYNECOLOGIC ONCOLOGY, 23(1), 101–104.

NUCLEAR DEOXYRIBONUCLEIC-ACID HETEROGENEITY OF OVARIAN BORDERLINE MALIGNANT SEROUS TUMORS
Fu, Y. S., Ro, J., Reagan, J. W., Hall, T. L., & Berek, J. (1986). NUCLEAR DEOXYRIBONUCLEIC-ACID HETEROGENEITY OF OVARIAN BORDERLINE MALIGNANT SEROUS TUMORS. OBSTETRICS AND GYNECOLOGY, 67(4), 478–482.

ADENOCARCINOMA OF THE UTERINE CERVIX - HISTOLOGIC VARIABLES ASSOCIATED WITH LYMPH-NODE METASTASIS AND SURVIVAL
Berek, J. S., Hacker, N. F., Fu, Y. S., SOKALE, J. R., LEUCHTER, R. C., & Lagasse, L. D. (1985). ADENOCARCINOMA OF THE UTERINE CERVIX - HISTOLOGIC VARIABLES ASSOCIATED WITH LYMPH-NODE METASTASIS AND SURVIVAL. OBSTETRICS AND GYNECOLOGY, 65(1), 46–52.

WHOLE ABDOMINAL RADIATION AS SALVAGE THERAPY FOR EPITHELIAL OVARIAN-CANCER
Hacker, N. F., Berek, J. S., Burnison, C. M., Heintz, A. P. M., Juillard, G. J. F., & Lagasse, L. D. (1985). WHOLE ABDOMINAL RADIATION AS SALVAGE THERAPY FOR EPITHELIAL OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 65(1), 60–66.

SYNERGISTIC EFFECTS OF COMBINATION SEQUENTIAL IMMUNOTHERAPIES IN A MURINE OVARIAN-CANCER MODEL
Berek, J. S., Lichtenstein, A. K., Knox, R. M., Jung, T. S., Rose, T. P., Cantrell, J. L., & ZIGHELBOIM, J. (1985). SYNERGISTIC EFFECTS OF COMBINATION SEQUENTIAL IMMUNOTHERAPIES IN A MURINE OVARIAN-CANCER MODEL. CANCER RESEARCH, 45(9), 4215–4218.

INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Knox, R. M., … ZIGHELBOIM, J. (1985). INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. CANCER RESEARCH, 45(9), 4447–4453.

LAPAROSCOPY IN THE MANAGEMENT OF PATIENTS WITH OVARIAN-CARCINOMA
Berek, J. S., & Hacker, N. F. (1983). LAPAROSCOPY IN THE MANAGEMENT OF PATIENTS WITH OVARIAN-CARCINOMA. CLINICS IN OBSTETRICS AND GYNAECOLOGY, 10(2), 213–222.

PHARMACOKINETICS OF IP CISPLATIN IN REFRACTORY OVARIAN-CARCINOMA
Pretorius, R. G., Hacker, N. F., Berek, J. S., Ford, L. C., Hoeschele, J. D., Butler, T. A., & Lagasse, L. D. (1983). PHARMACOKINETICS OF IP CISPLATIN IN REFRACTORY OVARIAN-CARCINOMA. CANCER TREATMENT REPORTS, 67(12), 1085–1092.

SUCCESSFUL IMMUNOTHERAPY WITH INTRAPERITONEAL CORNYEBACTERIUM-PARVUM IN A MURINE OVARIAN-CANCER MODEL IS ASSOCIATED WITH THE RECRUITMENT OF TUMOR-LYTIC NEUTROPHILS INTO THE PERITONEAL-CAVITY
Lichtenstein, A. K., Kahle, J., Berek, J., & ZIGHELBOIM, J. (1984). SUCCESSFUL IMMUNOTHERAPY WITH INTRAPERITONEAL CORNYEBACTERIUM-PARVUM IN A MURINE OVARIAN-CANCER MODEL IS ASSOCIATED WITH THE RECRUITMENT OF TUMOR-LYTIC NEUTROPHILS INTO THE PERITONEAL-CAVITY. JOURNAL OF IMMUNOLOGY, 133(1), 519–526.

RECTOSIGMOID COLECTOMY AND REANASTOMOSIS TO FACILITATE RESECTION OF PRIMARY AND RECURRENT GYNECOLOGIC CANCER
Berek, J. S., Hacker, N. F., & Lagasse, L. D. (1984). RECTOSIGMOID COLECTOMY AND REANASTOMOSIS TO FACILITATE RESECTION OF PRIMARY AND RECURRENT GYNECOLOGIC CANCER. OBSTETRICS AND GYNECOLOGY, 64(5), 715–720.

PREOPERATIVE RADIATION-THERAPY FOR LOCALLY ADVANCED VULVAR CANCER
Hacker, N. F., Berek, J. S., Juillard, G. J. F., & Lagasse, L. D. (1984). PREOPERATIVE RADIATION-THERAPY FOR LOCALLY ADVANCED VULVAR CANCER. CANCER, 54(10), 2056–2061.

ROLE OF INFLAMMATORY NEUTROPHILS IN ANTITUMOR EFFECTS INDUCED BY INTRAPERITONEAL ADMINISTRATION OF CORYNEBACTERIUM-PARVUM IN MICE
Lichtenstein, A. K., Berek, J., Kahle, J., & ZIGHELBOIM, J. (1984). ROLE OF INFLAMMATORY NEUTROPHILS IN ANTITUMOR EFFECTS INDUCED BY INTRAPERITONEAL ADMINISTRATION OF CORYNEBACTERIUM-PARVUM IN MICE. CANCER RESEARCH, 44(11), 5118–5123.

LYMPHOCYTE CYTO-TOXICITY IN THE PERITONEAL-CAVITY AND BLOOD OF PATIENTS WITH OVARIAN-CANCER
Berek, J. S., Bast, R. C., Lichtenstein, A., Hacker, N. F., Spina, C. A., Lagasse, L. D., … ZIGHELBOIM, J. (1984). LYMPHOCYTE CYTO-TOXICITY IN THE PERITONEAL-CAVITY AND BLOOD OF PATIENTS WITH OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 64(5), 708–714.

2ND-LOOK LAPAROTOMY IN STAGE-III EPITHELIAL OVARIAN-CANCER - CLINICAL-VARIABLES ASSOCIATED WITH DISEASE STATUS
Berek, J. S., Hacker, N. F., Lagasse, L. D., Poth, T., Resnick, B., & Nieberg, R. K. (1984). 2ND-LOOK LAPAROTOMY IN STAGE-III EPITHELIAL OVARIAN-CANCER - CLINICAL-VARIABLES ASSOCIATED WITH DISEASE STATUS. OBSTETRICS AND GYNECOLOGY, 64(2), 207–212.

ACTIVATION OF PERITONEAL LYMPHOCYTE CYTO-TOXICITY IN PATIENTS WITH OVARIAN-CANCER BY INTRAPERITONEAL TREATMENT WITH CORYNEBACTERIUM-PARVUM
Lichtenstein, A., Berek, J., Bast, R., Spina, C., Hacker, N., Knapp, R. C., & ZIGHELBOIM, J. (1984). ACTIVATION OF PERITONEAL LYMPHOCYTE CYTO-TOXICITY IN PATIENTS WITH OVARIAN-CANCER BY INTRAPERITONEAL TREATMENT WITH CORYNEBACTERIUM-PARVUM. JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 3(4), 371–378.

INDIVIDUALIZATION OF TREATMENT FOR STAGE-I SQUAMOUS-CELL VULVAR CARCINOMA
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Leuchter, R. S. (1984). INDIVIDUALIZATION OF TREATMENT FOR STAGE-I SQUAMOUS-CELL VULVAR CARCINOMA. OBSTETRICS AND GYNECOLOGY, 63(2), 155–162.

VAGINAL RECONSTRUCTION PERFORMED SIMULTANEOUSLY WITH PELVIC EXENTERATION
Berek, J. S., Hacker, N. F., & Lagasse, L. D. (1984). VAGINAL RECONSTRUCTION PERFORMED SIMULTANEOUSLY WITH PELVIC EXENTERATION. OBSTETRICS AND GYNECOLOGY, 63(3), 318–323.

IMMUNOTHERAPY WITH BIOCHEMICALLY DISSOCIATED FRACTIONS OF PROPIONIBACTERIUM ACNES IN A MURINE OVARIAN-CANCER MODEL
Berek, J. S., Cantrell, J. L., Lichtenstein, A. K., Hacker, N. F., Knox, R. M., Nieberg, R. K., … ZIGHELBOIM, J. (1984). IMMUNOTHERAPY WITH BIOCHEMICALLY DISSOCIATED FRACTIONS OF PROPIONIBACTERIUM ACNES IN A MURINE OVARIAN-CANCER MODEL. CANCER RESEARCH, 44(5), 1871–1875.

DELAYED VAGINAL RECONSTRUCTION IN THE FIBROTIC PELVIS FOLLOWING RADIATION OR PREVIOUS RECONSTRUCTION
Berek, J. S., Hacker, N. F., Lagasse, L. D., & Smith, M. L. (1983). DELAYED VAGINAL RECONSTRUCTION IN THE FIBROTIC PELVIS FOLLOWING RADIATION OR PREVIOUS RECONSTRUCTION. OBSTETRICS AND GYNECOLOGY, 61(6), 743–748.

MICROINVASIVE CARCINOMA OF THE VULVA
Hacker, N. F., Berek, J. S., Lagasse, L. D., & Nieberg, R. K. (1983). MICROINVASIVE CARCINOMA OF THE VULVA. OBSTETRICS AND GYNECOLOGY, 62(1), 134–135.

ESTROGEN AND PROGESTERONE RECEPTORS IN OVARIAN NEOPLASMS
Ford, L. C., Berek, J. S., Lagasse, L. D., Hacker, N. F., Heins, Y., Esmailian, F., … DELANGE, R. J. (1983). ESTROGEN AND PROGESTERONE RECEPTORS IN OVARIAN NEOPLASMS. GYNECOLOGIC ONCOLOGY, 15(3), 299–304.

SURGICAL-MANAGEMENT OF OVARIAN-CANCER
FARIASEISNER, R., Kim, Y. B., & Berek, J. S. (1994). SURGICAL-MANAGEMENT OF OVARIAN-CANCER. SEMINARS IN SURGICAL ONCOLOGY, 10(4), 268–275.

ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M. L., … Woodward, J. (1995). ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY. JOURNAL OF CLINICAL ONCOLOGY, 13(7), 1589–1599.

OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME
Berek, J. S. (1995). OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME. LANCET, 346(8969), 200–200.

RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER
Berek, J. S. (1995). RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 32(5), 1543–1544.

Advances in the biology of gynecologic cancer.
Gotlieb, W. H., & Berek, J. S. (1994). Advances in the biology of gynecologic cancer. Current Opinion in Oncology, 6(5), 513–518.

INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE
Berek, J. S. (1995). INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE. NEW ENGLAND JOURNAL OF MEDICINE, 332(10), 675–677.

INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN-CANCER - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP TRIAL
Braly, P. S., Berek, J. S., Blessing, J. A., Homesley, H. D., & Averette, H. (1995). INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN-CANCER - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP TRIAL. GYNECOLOGIC ONCOLOGY, 56(2), 164–168.

PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNANT OVARIAN EPITHELIAL NEOPLASMS
Parker, W. H., & Berek, J. S. (1994). PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNANT OVARIAN EPITHELIAL NEOPLASMS. OBSTETRICS AND GYNECOLOGY, 84(5), 897–897.

A MULTICENTER STUDY OF LAPAROSCOPIC MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN
Parker, W. H., Levine, R. L., Howard, F. M., SANSONE, B., & Berek, J. S. (1994). A MULTICENTER STUDY OF LAPAROSCOPIC MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 179(6), 733–737.

THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION, AND EXTENT OF CARCINOMATOSIS IN MINIMAL RESIDUAL STAGE-III EPITHELIAL OVARIAN-CANCER AFTER OPTIMAL PRIMARY CYTOREDUCTIVE SURGERY
FARIASEISNER, R., Teng, F., Oliveira, M., Leuchter, R., Karlan, B., Lagasse, L. D., & Berek, J. S. (1994). THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION, AND EXTENT OF CARCINOMATOSIS IN MINIMAL RESIDUAL STAGE-III EPITHELIAL OVARIAN-CANCER AFTER OPTIMAL PRIMARY CYTOREDUCTIVE SURGERY. GYNECOLOGIC ONCOLOGY, 55(1), 108–110.

LAPAROSCOPIC MANAGEMENT OF THE ADNEXAL MASS
Parker, W. H., & Berek, J. S. (1994). LAPAROSCOPIC MANAGEMENT OF THE ADNEXAL MASS. OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 21(1), 79–92.

MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER
Berek, J. S., & MARTINEZMAZA, T. (1994). MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER. JOURNAL OF REPRODUCTIVE MEDICINE, 39(4), 241–248.

Fine-needle aspiration cytology in the management of gynecologic oncology patients.
Layfield, L. J., & Berek, J. S. (1994). Fine-needle aspiration cytology in the management of gynecologic oncology patients. Cancer Treatment and Research, 70, 1–13.

SALVAGE THERAPY FOR RECURRENT AND REFRACTORY OVARIAN-CANCER WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY
Broun, E. R., Belinson, J. L., Berek, J. S., McIntosh, D., Hurd, D., Ball, H., & Williams, S. (1994). SALVAGE THERAPY FOR RECURRENT AND REFRACTORY OVARIAN-CANCER WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY. GYNECOLOGIC ONCOLOGY, 54(2), 142–146.

UTERINE SARCOMA IN PATIENTS OPERATED ON FOR PRESUMED LEIOMYOMA AND RAPIDLY GROWING LEIOMYOMA
Parker, W. H., Fu, Y. S., & Berek, J. S. (1994). UTERINE SARCOMA IN PATIENTS OPERATED ON FOR PRESUMED LEIOMYOMA AND RAPIDLY GROWING LEIOMYOMA. OBSTETRICS AND GYNECOLOGY, 83(3), 414–418.

CYTOKINE-INDUCED MODULATION OF TUMOR-SUPPRESSOR GENE-EXPRESSION IN OVARIAN-CANCER CELLS - UP-REGULATION OF P53 GENE-EXPRESSION AND INDUCTION OF APOPTOSIS BY TUMOR-NECROSIS-FACTOR-ALPHA
Gotlieb, W. H., Watson, J. M., Rezai, A., Johnson, M., MARTINEZMAZA, O., & Berek, J. S. (1994). CYTOKINE-INDUCED MODULATION OF TUMOR-SUPPRESSOR GENE-EXPRESSION IN OVARIAN-CANCER CELLS - UP-REGULATION OF P53 GENE-EXPRESSION AND INDUCTION OF APOPTOSIS BY TUMOR-NECROSIS-FACTOR-ALPHA. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 170(4), 1121–1130.

THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA
Hoskins, W. J., McGuire, W. P., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M., … Berek, J. S. (1994). THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 170(4), 974–980.

CONSERVATIVE AND INDIVIDUALIZED SURGERY FOR EARLY SQUAMOUS CARCINOMA OF THE VULVA - THE TREATMENT OF CHOICE FOR STAGE-I AND II (T1-2N0-1M0) DISEASE
FARIASEISNER, R., Cirisano, F. D., GROUSE, D., Leuchter, R. S., Karlan, B. Y., Lagasse, L. D., & Berek, J. S. (1994). CONSERVATIVE AND INDIVIDUALIZED SURGERY FOR EARLY SQUAMOUS CARCINOMA OF THE VULVA - THE TREATMENT OF CHOICE FOR STAGE-I AND II (T1-2N0-1M0) DISEASE. GYNECOLOGIC ONCOLOGY, 53(1), 55–58.

Advanced ovarian cancer. Tumour markers.
Rustin, G. J., Van der Burg, M. E., & Berek, J. S. (1993). Advanced ovarian cancer. Tumour markers. Annals of Oncology , 4, 71–77.

ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS
Allen, D. G., Baak, J., Belpomme, D., Berek, J. S., Bertelsen, K., Huinink, W. W. T., … DeVries, E. G. E. (1993). ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS. ANNALS OF ONCOLOGY, 4, 83–88.

MOLECULAR AND BIOLOGICAL FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER
Berek, J. S., MARTINEZMAZA, O., Hamilton, T., Trope, C., Kaern, J., Baak, J., & Rustin, G. J. S. (1993). MOLECULAR AND BIOLOGICAL FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER. Presented at the International Workshop on Advanced Ovarian Cancer: where Do We Stand and Where Do We Go, HELSINGOR,DENMARK: OXFORD UNIV PRESS.

PROGNOSTIC FACTORS FOR GROIN NODE METASTASIS IN SQUAMOUS-CELL CARCINOMA OF THE VULVA (A GYNECOLOGIC-ONCOLOGY-GROUP-STUDY)
Homesley, H. D., Bundy, B. N., Sedlis, A., YORDAN, E., Berek, J. S., Jahshan, A., & MORTEL, R. (1993). PROGNOSTIC FACTORS FOR GROIN NODE METASTASIS IN SQUAMOUS-CELL CARCINOMA OF THE VULVA (A GYNECOLOGIC-ONCOLOGY-GROUP-STUDY). GYNECOLOGIC ONCOLOGY, 49(3), 279–283.

CONSTITUTIVE PRODUCTION OF MACROPHAGE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-6 BY HUMAN OVARIAN SURFACE EPITHELIAL-CELLS
LIDOR, Y. J., Xu, F. J., MARTINEZMAZA, O., Olt, G. J., Marks, J. R., Berchuck, A., … Bast, R. C. (1993). CONSTITUTIVE PRODUCTION OF MACROPHAGE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-6 BY HUMAN OVARIAN SURFACE EPITHELIAL-CELLS. EXPERIMENTAL CELL RESEARCH, 207(2), 332–339.

SENSITIVITY OF DRUG-RESISTANT HUMAN OVARIAN TUMOR-CELL LINES TO COMBINED EFFECTS OF TUMOR-NECROSIS-FACTOR (TNF-ALPHA) AND DOXORUBICIN - FAILURE OF THE COMBINATION TO MODULATE THE MDR PHENOTYPE
Safrit, J. T., Berek, J. S., & Bonavida, B. (1993). SENSITIVITY OF DRUG-RESISTANT HUMAN OVARIAN TUMOR-CELL LINES TO COMBINED EFFECTS OF TUMOR-NECROSIS-FACTOR (TNF-ALPHA) AND DOXORUBICIN - FAILURE OF THE COMBINATION TO MODULATE THE MDR PHENOTYPE. GYNECOLOGIC ONCOLOGY, 48(2), 214–220.

Current management of invasive squamous carcinoma of the vulva.
Farias-Eisner, R., & Berek, J. S. (1993). Current management of invasive squamous carcinoma of the vulva. Clinics in Geriatric Medicine, 9(1), 131–143.

SOLITARY RECURRENT METASTASIS OF EPITHELIAL OVARIAN-CANCER IN THE SPLEEN
FARIASEISNER, R., Braly, P., & Berek, J. S. (1993). SOLITARY RECURRENT METASTASIS OF EPITHELIAL OVARIAN-CANCER IN THE SPLEEN. GYNECOLOGIC ONCOLOGY, 48(3), 338–341.

PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMENARCHAL FEMALE
Monk, B. J., NIEBERG, R., & Berek, J. S. (1993). PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMENARCHAL FEMALE. GYNECOLOGIC ONCOLOGY, 48(3), 389–393.

GROWTH-INHIBITION OF OVARIAN-CANCER CELLS INDUCED BY ANTISENSE IL-6 OLIGONUCLEOTIDES
Watson, J. M., Berek, J. S., & MARTINEZMAZA, O. (1993). GROWTH-INHIBITION OF OVARIAN-CANCER CELLS INDUCED BY ANTISENSE IL-6 OLIGONUCLEOTIDES. GYNECOLOGIC ONCOLOGY, 49(1), 8–15.

IMPACT OF CONTRACEPTION ON GYNECOLOGIC CANCERS
Herbst, A. L., & Berek, J. S. (1993). IMPACT OF CONTRACEPTION ON GYNECOLOGIC CANCERS. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 168(6), 1980–1985.

Evidence for a unifocal origin in familial ovarian cancer
Gallion, H. H., Guarino, D., DePriest, P. D., VANNAGELL, J. R., Vaccarello, L., Berek, J. S., & Pieretti, M. (1996). Evidence for a unifocal origin in familial ovarian cancer. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 174(4), 1102–1106.

Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma
Kim, Y. B., Berek, J. S., MARTINEZMAZA, O., & Satyaswaroop, P. G. (1996). Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma. GYNECOLOGIC ONCOLOGY, 61(1), 97–100.

OVARIAN-CANCER SCREENING - THE USE OF SERIAL COMPLEMENTARY TUMOR-MARKERS TO IMPROVE SENSITIVITY AND SPECIFICITY FOR EARLY DETECTION
Berek, J. S., & Bast, R. C. (1995). OVARIAN-CANCER SCREENING - THE USE OF SERIAL COMPLEMENTARY TUMOR-MARKERS TO IMPROVE SENSITIVITY AND SPECIFICITY FOR EARLY DETECTION. CANCER, 76(10), 2092–2096.

Mixed mesodermal sarcoma of the ovary in a young patient
Fowler, J. M., Nathan, L., Nieberg, R. K., & Berek, J. S. (1996). Mixed mesodermal sarcoma of the ovary in a young patient. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 65(2), 249–253.

Dysgerminoma: The role of conservative surgery
Casey, A. C., Bhodauria, S., Shapter, A., NIEBERG, R., Barek, J. S., & FARIASEISNER, R. (1996). Dysgerminoma: The role of conservative surgery. GYNECOLOGIC ONCOLOGY, 63(3), 352–357.

Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy-A Multicentered Study
Parker, Levine, Howard, SANSONE, & Berek. (1994). Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy-A Multicentered Study. Journal of the American Association of Gynecologic Laparoscopists, 1(4), S27-?

Complete debulking of epithelial ovarian cancer.
Berek, J. S. (1996). Complete debulking of epithelial ovarian cancer. Cancer Journal from Scientific American, 2(3), 132–133.

Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes.
Casey, A. C., & Berek, J. S. (1994). Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. Obstetrics and Gynecology, 84(4), 724–726.

Progress in ovarian cancer
Chen, L., & Berek, J. S. (1998). Progress in ovarian cancer. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 10(1), 51–56.

Reducing loss-to-follow-up among women with abnormal Pap smears - Results from a randomized trial testing an intensive follow-up protocol and economic incentives
Marcus, A. C., Kaplan, C. P., Crane, L. A., Berek, J. S., Bernstein, G., Gunning, J. E., & McClatchey, M. W. (1998). Reducing loss-to-follow-up among women with abnormal Pap smears - Results from a randomized trial testing an intensive follow-up protocol and economic incentives. MEDICAL CARE, 36(3), 397–410.

Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer.
Kim, Y. B., Ghosh, K., Ainbinder, S., & Berek, J. S. (1998). Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer. Cancer Treatment and Research, 95, 253–276.

Psammocarcinoma with an aggressive course
Poggi, S. H., Bristow, R. E., Nieberg, R. K., & Berek, J. S. (1998). Psammocarcinoma with an aggressive course. OBSTETRICS AND GYNECOLOGY, 92(4), 659–661.

Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model
Dorigo, O., Shawler, D. L., Royston, I., SOBOL, R. E., Berek, J. S., & Fakhrai, H. (1998). Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. GYNECOLOGIC ONCOLOGY, 71(2), 204–210.

A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma. A gynecologic oncology group study
Feun, L. G., Blessing, J. A., Major, F. J., Disaia, P. J., Alvarez, R. D., & Berek, J. S. (1998). A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma. A gynecologic oncology group study. GYNECOLOGIC ONCOLOGY, 71(3), 410–415.

Association of lymphadenectomy and survival in stage I ovarian cancer patients - In reply
Chan, J. K., Munro, E., Cheung, M., Husain, A., Teng, N. N., Berek, J. S., & Osann, K. (2007). Association of lymphadenectomy and survival in stage I ovarian cancer patients - In reply. OBSTETRICS AND GYNECOLOGY, 109(4), 1000–1001.

Access to gynecologic oncologists and its impact on survival of women with epithelial ovarian cancer
Chan, J. K., Shin, J. Y., Husain, A., Teng, N. N., Berek, J. S., Kapp, D. S., … O'Malley, C. (2007). Access to gynecologic oncologists and its impact on survival of women with epithelial ovarian cancer. GYNECOLOGIC ONCOLOGY, 104(3), S23–S23.

Racial disparities in the surgical treatment of epithelial ovarian cancer in the United States
Chan, J. K., Zhang, M., Hu, J., Shin, J. Y., Husain, A., Teng, N. N., … Osann, K. (2007). Racial disparities in the surgical treatment of epithelial ovarian cancer in the United States. GYNECOLOGIC ONCOLOGY, 104(3), S31–S31.

A multivariate analysis of vulvar melanomas: A study of 359 patients
Sugiyama, V. E., Shin, J. Y., Osann, K., Kapp, D. S., Husain, A., Teng, N. N., … Chan, J. K. (2007). A multivariate analysis of vulvar melanomas: A study of 359 patients. GYNECOLOGIC ONCOLOGY, 104(3), S5–S6.

Factors responsible for the increase in death rate of women diagnosed with uterine corpus cancer
Ueda, S. M., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., Berek, J. S., … Chan, J. K. (2007). Factors responsible for the increase in death rate of women diagnosed with uterine corpus cancer. GYNECOLOGIC ONCOLOGY, 104(3), S8–S8.

The number of lymph nodes with metastatic disease portends for a poorer prognosis in women with stage IIIC-IV endometrioid uterine cancer.
Chan, J. K., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., Berek, J. S., & Kapp, D. S. (2006). The number of lymph nodes with metastatic disease portends for a poorer prognosis in women with stage IIIC-IV endometrioid uterine cancer. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 265S–265S.

The. role of extensive lymphadenectomy in stage I ovarian cancer.
Munro, E. G., Lee, N. K., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., … Chan, J. K. (2006). The. role of extensive lymphadenectomy in stage I ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 272S–272S.

The impact of lymphadenectomy in women with endometrioid uterine cancer: A study of 39,396 women.
Lee, N. K., Wu, H., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., … Chan, J. K. (2006). The impact of lymphadenectomy in women with endometrioid uterine cancer: A study of 39,396 women. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 256S–256S.

The role of surgical staging in grade 1 endometrioid corpus cancer.
Chan, J. K., Guo, H., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., … Kapp, D. S. (2006). The role of surgical staging in grade 1 endometrioid corpus cancer. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 258S–258S.

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
Zang, R. Y., Harter, P., Chi, D. S., Sehouli, J., Jiang, R., Trope, C. G., … Berek, J. S. (2011). Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. BRITISH JOURNAL OF CANCER, 105(7), 890–896.

A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection
Tian, W.-J., Chi, D. S., Sehouli, J., Trope, C. G., Jiang, R., Ayhan, A., … Harter, P. (2012). A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection. ANNALS OF SURGICAL ONCOLOGY, 19(2), 597–604.

Abagovomab for ovarian cancer
Pfisterer, J., Harter, P., Simonelli, C., Peters, M., Berek, J., Sabbatini, P., & du Bois, A. (2011). Abagovomab for ovarian cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 11(3), 395–403.

Her2neu over-expression and PI3kinase/Akt pathway activation in Paget's disease of the vulva.
Stenson, A., Behjatnia, B., Shamonki, J., Rao, J., Karam, A., Berek, J., & Dorigo, O. (2008). Her2neu over-expression and PI3kinase/Akt pathway activation in Paget's disease of the vulva. REPRODUCTIVE SCIENCES, 15(2), 307A–307A.

Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., … Balkwill, F. R. (2011). Rethinking ovarian cancer: recommendations for improving outcomes. NATURE REVIEWS CANCER, 11(10), 719–725.

The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade
Kandalaft, L. E., Singh, N., Liao, J. B., Facciabene, A., Berek, J. S., Powell, D. J., & Coukos, G. (2010). The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade. GYNECOLOGIC ONCOLOGY, 116(2), 222–33.

A statement on abortion by 100A professors of obstetrics: 40 years later
Archer, D. F., Autry, A. (M., Barbieri, R. L., Berek, J. S., Berga, S. L., Bernstein, I. M., … Yankowitz, J. (2013). A statement on abortion by 100A professors of obstetrics: 40 years later. CONTRACEPTION, 88(4), 568–76.

Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.
Hu, T., Chung, Y. M., Guan, M., Ma, M., Ma, J., Berek, J. S., & Hu, M. C. T. (2014). Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. Scientific Reports, 4, 5810-?

Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53.
Park, S.-H., Lee, J. H., Berek, J. S., & Hu, M. C. T. (2014). Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. International Journal of Oncology, 45(4), 1691–98.

Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer
Mills, A. M., Liou, S., Ford, J. M., Berek, J. S., Pai, R. K., & Longacre, T. A. (2014). Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 38(11), 1501–9.

Immunotherapeutic approaches to ovarian cancer treatment.
Chester, C., Dorigo, O., Berek, J. S., & Kohrt, H. (2015). Immunotherapeutic approaches to ovarian cancer treatment. Journal for Immunotherapy of Cancer, 3, 7-?

INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Knox, R. M., … ZIGHELBOIM, J. (1986). INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. SEMINARS IN ONCOLOGY, 13(3), 61–71.

Chemotherapy for ovarian cancer
Berek, J. S., Markman, M., McGuire, W. P., Thigpen, J. T., & OZOLS, R. F. (1998). Chemotherapy for ovarian cancer. Presented at the XV FIGO World Congress of Gynaecology and Obstetrics, COPENHAGEN,DENMARK: PARTHENON PUBLISHING GROUP LTD.

MANAGEMENT OF POST-EXENTERATION PERINEAL HERNIAS BY MYOCUTANEOUS AXIAL FLAPS
Leuchter, R. S., Lagasse, L. D., Hacker, N. F., & Berek, J. S. (1982). MANAGEMENT OF POST-EXENTERATION PERINEAL HERNIAS BY MYOCUTANEOUS AXIAL FLAPS. GYNECOLOGIC ONCOLOGY, 14(1), 15–22.

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
Fleming, G. F., Sill, M. W., Darcy, K. M., McMeekin, D. S., Thigpen, J. T., Adler, L. M., … Fiorica, J. V. (2010). Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 116(1), 15–20.

SURVIVAL OF PATIENTS FOLLOWING SECONDARY CYTOREDUCTIVE SURGERY IN OVARIAN-CANCER
Berek, J. S., Hacker, N. F., Lagasse, L. D., Nieberg, R. K., & Elashoff, R. M. (1983). SURVIVAL OF PATIENTS FOLLOWING SECONDARY CYTOREDUCTIVE SURGERY IN OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 61(2), 189–193.

LEVATOR ANI TRANSPOSITION FOR ANAL INCOMPETENCE SECONDARY TO SPHINCTER DAMAGE
Berek, J. S., Lagasse, L. D., Hacker, N. F., & Leuchter, R. S. (1982). LEVATOR ANI TRANSPOSITION FOR ANAL INCOMPETENCE SECONDARY TO SPHINCTER DAMAGE. OBSTETRICS AND GYNECOLOGY, 59(1), 108–112.

Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer A Phase II Study
Berek, J. S., Edwards, R. P., Parker, L. P., DeMars, L. R., Herzog, T. J., Lentz, S. S., … Krasner, C. N. (2014). Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer A Phase II Study. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 24(9), 1583–89.

LOWER URINARY-TRACT RESECTION AS PART OF CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER
Berek, J. S., Hacker, N. F., Lagasse, L. D., & Leuchter, R. S. (1982). LOWER URINARY-TRACT RESECTION AS PART OF CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER. GYNECOLOGIC ONCOLOGY, 13(1), 87–92.

Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
Grisham, R. N., Berek, J., Pfisterer, J., & Sabbatini, P. (2011). Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. IMMUNOTHERAPY, 3(2), 153–162.

PRIMARY CYTOREDUCTIVE SURGERY FOR EPITHELIAL OVARIAN-CANCER
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Elashoff, R. M. (1983). PRIMARY CYTOREDUCTIVE SURGERY FOR EPITHELIAL OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 61(4), 413–420.

Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study
Simpkins, F., Flores, A., Chu, C., Berek, J. S., Lucci, J., Murray, S., … Coukos, G. (2013). Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study. CANCER IMMUNOLOGY RESEARCH, 1(3), 168–78.

Complications of pelvic radiation therapy for gynecologic malignancies in elderly women
McGonigle, K. F., Lavey, R. S., Juillard, G., & Berek, J. S. (1996). Complications of pelvic radiation therapy for gynecologic malignancies in elderly women. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 6(2), 149–155.

PERITONEAL ADENOCARCINOMA (SEROUS) OF MULLERIAN TYPE - A SUBGROUP OF WOMEN PRESENTING WITH PERITONEAL CARCINOMATOSIS
Fowler, J. M., Nieberg, R. K., SCHOOLER, T. A., & Berek, J. S. (1994). PERITONEAL ADENOCARCINOMA (SEROUS) OF MULLERIAN TYPE - A SUBGROUP OF WOMEN PRESENTING WITH PERITONEAL CARCINOMATOSIS. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 4(1), 43–51.

CORRELATION OF ENDOCERVICAL CURETTAGE WITH SUBSEQUENT CONE BIOPSY IN THE INVESTIGATION OF ABNORMAL CERVICAL CYTOLOGY
TAKAMI, C. Y., Nieberg, R. K., & Berek, J. S. (1991). CORRELATION OF ENDOCERVICAL CURETTAGE WITH SUBSEQUENT CONE BIOPSY IN THE INVESTIGATION OF ABNORMAL CERVICAL CYTOLOGY. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1(3), 97–103.

INTRAPERITONEAL IMMUNOTHERAPY OF HUMAN OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM
Bast, R. C., Berek, J. S., Obrist, R., Griffiths, C. T., Berkowitz, R. S., Hacker, N. F., … Knapp, R. C. (1983). INTRAPERITONEAL IMMUNOTHERAPY OF HUMAN OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM. CANCER RESEARCH, 43(3), 1395–1401.

MANAGEMENT OF REGIONAL LYMPH-NODES AND THEIR PROGNOSTIC INFLUENCE IN VULVAR CANCER
Hacker, N. F., Berek, J. S., Lagasse, L. D., Leuchter, R. S., & MOORE, J. G. (1983). MANAGEMENT OF REGIONAL LYMPH-NODES AND THEIR PROGNOSTIC INFLUENCE IN VULVAR CANCER. OBSTETRICS AND GYNECOLOGY, 61(4), 408–412.

SUPERFICIALLY INVASIVE VULVAR CANCER WITH NODAL METASTASES
Hacker, N. F., Nieberg, R. K., Berek, J. S., Leuchter, R. S., LUCAS, W. E., Tamimi, H. K., … Lagasse, L. D. (1983). SUPERFICIALLY INVASIVE VULVAR CANCER WITH NODAL METASTASES. GYNECOLOGIC ONCOLOGY, 15(1), 65–77.

ESTROGEN AND PROGESTERONE-RECEPTOR SITES IN MALIGNANCIES OF THE UTERINE CERVIX, VAGINA, AND VULVA
Ford, L. C., Berek, J. S., Lagasse, L. D., Hacker, N. F., HEINS, Y. L., & DELANGE, R. J. (1983). ESTROGEN AND PROGESTERONE-RECEPTOR SITES IN MALIGNANCIES OF THE UTERINE CERVIX, VAGINA, AND VULVA. GYNECOLOGIC ONCOLOGY, 15(1), 27–31.

PRIMARY-CARCINOMA OF THE BARTHOLIN GLAND - A REPORT OF 14 CASES AND REVIEW OF THE LITERATURE
Leuchter, R. S., Hacker, N. F., Voet, R. L., Berek, J. S., Townsend, D. E., & Lagasse, L. D. (1982). PRIMARY-CARCINOMA OF THE BARTHOLIN GLAND - A REPORT OF 14 CASES AND REVIEW OF THE LITERATURE. OBSTETRICS AND GYNECOLOGY, 60(3), 361–368.

RADICAL VULVECTOMY AND BILATERAL INGUINAL LYMPHADENECTOMY THROUGH SEPARATE GROIN INCISIONS
Hacker, N. F., Leuchter, R. S., Berek, J. S., CASTALDO, T. W., & Lagasse, L. D. (1981). RADICAL VULVECTOMY AND BILATERAL INGUINAL LYMPHADENECTOMY THROUGH SEPARATE GROIN INCISIONS. OBSTETRICS AND GYNECOLOGY, 58(5), 574–579.

RECENT PROGRESS IN THE TREATMENT OF EPITHELIAL OVARIAN MALIGNANCY
Berek, J. S., Hacker, N. F., & Lagasse, L. D. (1982). RECENT PROGRESS IN THE TREATMENT OF EPITHELIAL OVARIAN MALIGNANCY. WESTERN JOURNAL OF MEDICINE, 137(4), 273–277.

UTERINE CORPUS AND CERVICAL-CANCER
Berek, J. S., Hatch, K. D., Hacker, N. F., & Young, R. C. (1988). UTERINE CORPUS AND CERVICAL-CANCER. CURRENT PROBLEMS IN CANCER, 12(2), 65–129.

Conclusions and recommendations from the Helene Harris Memorial Trust Sixth Biennial International Forum on Ovarian Cancer, May 10-14, 1997, Los Angeles, California, USA
Sharp, F., Blackett, A. D., Berek, J. S., & Bast, R. C. (1997). Conclusions and recommendations from the Helene Harris Memorial Trust Sixth Biennial International Forum on Ovarian Cancer, May 10-14, 1997, Los Angeles, California, USA. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 7(5), 416–424.

ADENOCARCINOMA OF THE UTERINE CERVIX
Berek, J. S., CASTALDO, T. W., Hacker, N. F., PETRILLI, E. S., Lagasse, L. D., & MOORE, J. G. (1981). ADENOCARCINOMA OF THE UTERINE CERVIX. CANCER, 48(12), 2734–2741.

LAPAROSCOPY FOR 2ND-LOOK EVALUATION IN OVARIAN-CANCER
Berek, J. S., Griffiths, C. T., & Leventhal, J. M. (1981). LAPAROSCOPY FOR 2ND-LOOK EVALUATION IN OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 58(2), 192–198.

CYTOTOXICITY OF NEW AZA-ALKYL LYSOPHOSPHOLIPIDS AGAINST DRUG-SENSITIVE AND RESISTANT HUMAN OVARIAN TUMOR-CELL LINES - ROLE OF FREE-RADICALS AND POTENTIATION OF CYTOTOXICITY BY TNF-ALPHA AND CDDP
Hourizadeh, A., Broquet, C., MENCIAHUERTA, J. M., BRAQUET, P., Berek, J., & Bonavida, B. (1994). CYTOTOXICITY OF NEW AZA-ALKYL LYSOPHOSPHOLIPIDS AGAINST DRUG-SENSITIVE AND RESISTANT HUMAN OVARIAN TUMOR-CELL LINES - ROLE OF FREE-RADICALS AND POTENTIATION OF CYTOTOXICITY BY TNF-ALPHA AND CDDP. ONCOLOGY REPORTS, 1(6), 1253–1259.

In reply.
Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., … Manson, J. A. E. (2013). In reply. Obstetrics and Gynecology, 122(2), 396-?

First-Line Therapy in Ovarian Cancer Trials
Thigpen, T., duBois, A., McAlpine, J., DiSaia, P., Fujiwara, K., Hoskins, W., … Stuart, G. C. E. (2011). First-Line Therapy in Ovarian Cancer Trials. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 21(4), 756–762.

CARCINOMA OF THE CERVIX ASSOCIATED WITH PREGNANCY
Hacker, N. F., Berek, J. S., Lagasse, L. D., Charles, E. H., SAVAGE, E. W., & MOORE, J. G. (1982). CARCINOMA OF THE CERVIX ASSOCIATED WITH PREGNANCY. OBSTETRICS AND GYNECOLOGY, 59(6), 735–747.

CONCLUSIONS AND RECOMMENDATIONS FROM THE HELENE-HARRIS-MEMORIAL-TRUST 5TH BIENNIAL INTERNATIONAL FORUM ON OVARIAN-CANCER, MAY 4-7, 1995, GLASGOW, UK
Sharp, F., Blackett, A. D., Leake, R. E., & Berek, J. S. (1995). CONCLUSIONS AND RECOMMENDATIONS FROM THE HELENE-HARRIS-MEMORIAL-TRUST 5TH BIENNIAL INTERNATIONAL FORUM ON OVARIAN-CANCER, MAY 4-7, 1995, GLASGOW, UK. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 5(6), 449–458.

MASSIVE EXUDATIVE ASCITES PRODUCED FROM A TUBAL PSEUDOCYST IN CHRONIC PELVIC INFLAMMATORY DISEASE
Berek, J. S., & Darney, P. D. (1979). MASSIVE EXUDATIVE ASCITES PRODUCED FROM A TUBAL PSEUDOCYST IN CHRONIC PELVIC INFLAMMATORY DISEASE. OBSTETRICS AND GYNECOLOGY, 54(4), 490–492.

PERINATAL-MORTALITY IN TERM AND POST-TERM BIRTHS
Stubblefield, P. G., & Berek, J. S. (1980). PERINATAL-MORTALITY IN TERM AND POST-TERM BIRTHS. OBSTETRICS AND GYNECOLOGY, 56(6), 676–682.

EVALUATION OF A BALLOON DILATOR BEFORE 2ND-TRIMESTER ABORTION BY VACUUM CURETTAGE
Stubblefield, P. G., Frederiksen, M. C., Berek, J. S., GATTER, M. A., Kayman, D. J., & BORTEN, M. (1979). EVALUATION OF A BALLOON DILATOR BEFORE 2ND-TRIMESTER ABORTION BY VACUUM CURETTAGE. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 135(2), 199–201.

ANATOMIC AND CLINICAL CORRELATES OF UTERINE PERFORATION
Berek, J. S., & Stubblefield, P. G. (1979). ANATOMIC AND CLINICAL CORRELATES OF UTERINE PERFORATION. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 135(2), 181–184.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Boehm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., … Balkwill, F. R. (2015). Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. NATURE REVIEWS CANCER, 15(11), 668–79.

Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C., & Friedlander, M. (2015). Cancer of the ovary, fallopian tube, and peritoneum. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 131, S111–S122.

U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women?
Parker, W. H., Kaunitz, A. M., Pritts, E. A., Olive, D. L., Chalas, E., Clarke-Pearson, D. L., & Berek, J. S. (2016). U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women? Obstetrics and Gynecology, 127(1), 18–22.

Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation
Lum, D. A., Sokol, E. R., Berek, J. S., Schulkin, J., Chen, L., McElwain, C.-A., & Wright, J. D. (2016). Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 23(4), 548–56.

In Reply.
Parker, W. H., Kaunitz, A. M., Pritts, E. A., Olive, D. L., Chalas, E., Clarke-Pearson, D. L., & Berek, J. S. (2016). In Reply. Obstetrics and Gynecology, 127(5), 966–67.

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial.
Gray, H. J., Benigno, B., Berek, J., Chang, J., Mason, J., Mileshkin, L., … Goh, J. C. (2016). Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer, 4, 34-?

TUMOR-MARKERS
Rustin, G. J. S., VANDERBURG, M. E. L., & Berek, J. S. (1993). TUMOR-MARKERS. Presented at the International Workshop on Advanced Ovarian Cancer: where Do We Stand and Where Do We Go, HELSINGOR,DENMARK: OXFORD UNIV PRESS.

INTRAPERITONEAL RECOMBINANT INTERFERON-ALPHA-2 FOR SALVAGE IMMUNOTHERAPY IN PERSISTENT EPITHELIAL OVARIAN-CANCER
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., Knox, R. M., … ZIGHELBOIM, J. (1985). INTRAPERITONEAL RECOMBINANT INTERFERON-ALPHA-2 FOR SALVAGE IMMUNOTHERAPY IN PERSISTENT EPITHELIAL OVARIAN-CANCER. CANCER TREATMENT REVIEWS, 12, 23–32.

Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo
Park, S.-H., Chung, Y. M., Ma, J., Yang, Q., Berek, J. S., & Hu, M. C. T. (2016). Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo. ONCOTARGET, 7(27), 42110–25.

5th Ovarian Cancer Consensus Conference: Individualized Therapy and Patient Factors.
McGee, J., Bookman, M., Harter, P., Marth, C., McNeish, I., Moore, K. N., … Ochiai, K. (2017). 5th Ovarian Cancer Consensus Conference: Individualized Therapy and Patient Factors. Annals of Oncology .

Impact of the 2014 FDA Warnings Against Laparoscopic Power Morcellation.
Lum, D., Berek, J. S., Sheikhi, F., & Sokol, E. R. (2015). Impact of the 2014 FDA Warnings Against Laparoscopic Power Morcellation. Journal of Minimally Invasive Gynecology, 22(6S), S77-?

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., … Matulonis, U. A. (2016). Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 375(22), 2154–64.

Immunotherapy in ovarian cancer.
Krishnan, V., Berek, J. S., & Dorigo, O. (2016). Immunotherapy in ovarian cancer. Current Problems in Cancer.

The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis.
Pritts, E. A., Vanness, D. J., Berek, J. S., Parker, W., Feinberg, R., Feinberg, J., & Olive, D. L. (2015). The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecological Surgery, 12(3), 165–77.

Immunotherapy in ovarian cancer
Krishnan, V., Berek, J. S., & Dorigo, O. (2017). Immunotherapy in ovarian cancer. CURRENT PROBLEMS IN CANCER, 41(1), 48–63.

US Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas
Parker, W. H., Kaunitz, A. M., Pritts, E. A., Olive, D. L., Chalas, E., Clarke-Pearson, D. L., & Berek, J. S. (2016). US Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas. OBSTETRICS AND GYNECOLOGY, 127(1), 18–22.

A statement on abortion by 100 professors of obstetrics: 40 years later
Archer, D. F., Autry, A. (M., Barbieri, R. L., Berek, J. S., Berga, S. L., Bernstein, I. M., … Yankowitz, J. (2013). A statement on abortion by 100 professors of obstetrics: 40 years later. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 209(3), 193–99.

Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry
Gonzalez, V. D., Samusik, N., Chen, T. J., Savig, E. S., Aghaeepour, N., Quigley, D. A., … Fantl, W. J. (2018). Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. CELL REPORTS, 22(7), 1875–88.

30 years of Current Opinion in Obstetrics and Gynecology: looking back and looking forward
Berek, J. S., & Fairbairn, S. (2018). 30 years of Current Opinion in Obstetrics and Gynecology: looking back and looking forward. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 30(2), 99.

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)
Roncolato, F. T., Berton-Rigaud, D., O'Connell, R., Lanceley, A., Sehouli, J., Buizen, L., … Friedlander, M. (2018). Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). GYNECOLOGIC ONCOLOGY, 148(1), 36–41.

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
King, M. T., Stockler, M. R., O'Connell, R. L., Buizen, L., Joly, F., Lanceley, A., … Friedlander, M. L. (2018). Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. QUALITY OF LIFE RESEARCH, 27(1), 59–74.

Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign Indications.
Chalas, E., Clarke-Pearson, D., & Berek, J. S. (2018). Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign Indications. Obstetrics and Gynecology, 132(2), 519.

A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer
Simpkins, F., Flores, A. M., Chu, C., Lucci, J. A., Berek, J. S., Coukos, G., … Toso, J. F. (2012). A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(15).

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
Oza, A. M., Matulonis, U. A., Malander, S., Hudgens, S., Sehouli, J., del Campo, J. M., … Mirza, M. R. (2018). Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. LANCET ONCOLOGY, 19(8), 1117–25.

SYK promotes tumor progression in ovarian cancer cell lines
Sultan, A., Wang, C. Y., Duran, G. E., Francisco, E. B., Berek, J. S., & Sikic, B. I. (2011). SYK promotes tumor progression in ovarian cancer cell lines. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation"
Parker, W. H., Berek, J. S., Pritts, E. A., Olive, D., Chalas, E., & Clarke-Pearson, D. (2018). Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation". JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 25(6), 1113.

Cancer of the ovary, fallopian tube, and peritoneum.
Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018). Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 143 Suppl 2, 59–78.

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study
Roncolato, F. T., Joly, F., O'Connell, R., Lanceley, A., Hilpert, F., Buizen, L., … Friedlander, M. (2017). Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. ONCOLOGIST, 22(9), 1117–24.

Reply to B.O. Anderson et al.
Chuang, L. T., El Saghir, N. S., Temin, S., & Berek, J. S. (2017). Reply to B.O. Anderson et al. Journal of Global Oncology, 3(1), 89–92.

Salpingo-Oophorectomy at the Time of Benign Hysterectomy: A Systematic Review
Parker, W. H., Broder, M. S., Berek, J. S., & Manson, J. A. E. (2017). Salpingo-Oophorectomy at the Time of Benign Hysterectomy: A Systematic Review. OBSTETRICS AND GYNECOLOGY, 129(1), 202.

Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline.
Chuang, L. T., Temin, S., Camacho, R., Duenas-Gonzalez, A., Feldman, S., Gultekin, M., … Berek, J. S. (2016). Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. Journal of Global Oncology, 2(5), 311–40.

Management and Care of Women With Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline
Chuang, L. T., Feldman, S., Nakisige, C., Temin, S., & Berek, J. S. (2016). Management and Care of Women With Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. JOURNAL OF CLINICAL ONCOLOGY, 34(27), 3354–U338.

Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary
Chuang, L. T., Temin, S., & Berek, J. S. (2016). Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. JOURNAL OF ONCOLOGY PRACTICE, 12(7), 693-+.

Can Arts and Communication Programs Improve Physician Wellness and Mitigate Physician Suicide?
Genovese, J. M., & Berek, J. S. (2016). Can Arts and Communication Programs Improve Physician Wellness and Mitigate Physician Suicide? JOURNAL OF CLINICAL ONCOLOGY, 34(15), 1820-+.

An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas
Parker, W., Berek, J. S., Pritts, E., Olive, D., Kaunitz, A. M., Chalas, E., … DeLancey, J. (2016). An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 23(3), 303–8.

The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis
Pritts, E. A., Vanness, D. J., Berek, J. S., Parker, W., Feinberg, R., Feinberg, J., & Olive, D. L. (2015). The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. GYNECOLOGICAL SURGERY, 12(3), 165–77.

BASELINE PREDICTORS OF EARLY TREATMENT FAILURE IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) RECEIVING >= 3 LINES OF CHEMOTHERAPY- THE GYNAECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)
Roncolato, F., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., … Kok, P.-S. (2015). BASELINE PREDICTORS OF EARLY TREATMENT FAILURE IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) RECEIVING >= 3 LINES OF CHEMOTHERAPY- THE GYNAECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS). Asia-Pacific Journal of Clinical Oncology, 11, 125.

IS IT TIME TO CHANGE THE PRIMARY ENDPOINT IN CLINICAL TRIALS IN RECURRENT OVARIAN CANCER (ROC)? SYMPTOM BURDEN AND OUTCOMES IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE ROC RECEIVING >= 3 LINES OF CHEMOTHERAPY (PPS) - THE GYNECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)
Friedlander, M., Stockler, M., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., … King, M. T. (2015). IS IT TIME TO CHANGE THE PRIMARY ENDPOINT IN CLINICAL TRIALS IN RECURRENT OVARIAN CANCER (ROC)? SYMPTOM BURDEN AND OUTCOMES IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE ROC RECEIVING >= 3 LINES OF CHEMOTHERAPY (PPS) - THE GYNECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS). Asia-Pacific Journal of Clinical Oncology, 11, 111.

Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC)
King, M., Stockler, M., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., … Friedlander, M. (2015). Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC). QUALITY OF LIFE RESEARCH, 24, 22–23.

ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Mirza, M. R., Mortensen, C. E., Avall-Lundqvist, E., Bjorge, L., Berek, J. S., Herrstedt, J., … Maenpaa, J. (2015). ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. JOURNAL OF CLINICAL ONCOLOGY, 33(15).

Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS >= 3) recurrent ovarian cancer (ROC) receiving >= 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).
Roncolato, F. T., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., … Friedlander, M. (2015). Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS >= 3) recurrent ovarian cancer (ROC) receiving >= 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). JOURNAL OF CLINICAL ONCOLOGY, 33(15).

Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/ refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3)-The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).
Friedlander, M., Stockler, M. R., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., … King, M. T. (2015). Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/ refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3)-The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). JOURNAL OF CLINICAL ONCOLOGY, 33(15).

A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).
Matulonis, U., Mahner, S., Wenham, R. M., Ledermann, J. A., Monk, B. J., Campo, J. M. D., … Mirza, M. R. (2014). A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). JOURNAL OF CLINICAL ONCOLOGY, 32(15).

FOXO3 tumor suppressor and out-FOXing cancer: Pathways to drug discovery
Hu, T., Chung, Y. M., Park, S.-H., Ma, J., Berek, J. S., & Hu, M. C.-T. (2014). FOXO3 tumor suppressor and out-FOXing cancer: Pathways to drug discovery. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 34, S120.

Centralized independent disease status adjudication for maintenance treatment evaluation in advanced ovarian cancer setting: A critical analysis of the MIMOSA trial experience.
Scartoni, S., Pfisterer, J., Sabbatini, P., Berek, J. S., Bertolotti, M., Contini, M., … Simonelli, C. (2013). Centralized independent disease status adjudication for maintenance treatment evaluation in advanced ovarian cancer setting: A critical analysis of the MIMOSA trial experience. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

Effect of metformin on recurrence-free survival and overall survival in diabetic patients affected by advanced ovarian cancer
Simonelli, C., Bertolotti, M., Sabbatini, P., Berek, J. S., Pfisterer, J., Binaschi, M., … Capriati, A. (2013). Effect of metformin on recurrence-free survival and overall survival in diabetic patients affected by advanced ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study EDITORIAL COMMENT
Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., … Manson, J. A. E. (2013). Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study EDITORIAL COMMENT. OBSTETRICAL & GYNECOLOGICAL SURVEY, 68(8), 561–63.

Multidisciplinary Approach to Diagnosis and Treatment of Early Cancer
Fuh, K. C., & Berek, J. S. (2014). Multidisciplinary Approach to Diagnosis and Treatment of Early Cancer. GYNECOLOGIC CANCERS: A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND MANAGEMENT, 179–84.

A study of autologous dendritic cell therapy targeting mucin-1 for treatment of patients with epithelial ovarian cancer in first remission.
Berek, J. S., Goh, J. C., Gray, H. J., Fiorica, J., & Mason, J. R. (2012). A study of autologous dendritic cell therapy targeting mucin-1 for treatment of patients with epithelial ovarian cancer in first remission. JOURNAL OF CLINICAL ONCOLOGY, 30(15).

NEZHAT'S OPERATIVE GYNECOLOGIC LAPAROSCOPY AND HYSTEROSCOPY Forewords
Krummel, T. M., Giudice, L. C., Cohen, C. J., & Berek, J. S. (2008). NEZHAT'S OPERATIVE GYNECOLOGIC LAPAROSCOPY AND HYSTEROSCOPY Forewords. NEZHAT'S OPERATIVE GYNECOLOGIC LAPAROSCOPY AND HYSTEROSCOPY, 3RD EDITION, XIII-XV.

Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy: Recommendations Based on Risk of Ovarian Cancer Reply
Berek, J. S. (2011). Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy: Recommendations Based on Risk of Ovarian Cancer Reply. OBSTETRICS AND GYNECOLOGY, 117(2), 404.

Long-Term Implications of Oophorectomy at the Time of Hysterectomy for Benign Disease
Shoupe, D., & Berek, J. S. (2010). Long-Term Implications of Oophorectomy at the Time of Hysterectomy for Benign Disease. AMENORRHEA: A CASE-BASED, CLINICAL GUIDE, 187–201.

TLR3 agonists as immunotherapeutic agents
Nicodemus, C. F., & Berek, J. S. (2010). TLR3 agonists as immunotherapeutic agents. IMMUNOTHERAPY, 2(2), 137–40.

Ovarian Conservation and Long-Term Health Outcomes in the Nurses' Health Study
Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., … Manson, J. A. E. (2009). Ovarian Conservation and Long-Term Health Outcomes in the Nurses' Health Study. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS.